Peregrine Pharmaceuticals (NASDAQ:PPHM)’s shares gained 6.53% to $1.96. The company on Apr. 7 announced data from studies demonstrating that an equivalent antibody to Peregrine’s lead immunotherapeutic antibody candidate bavituximab administered with stereotactic body radiation therapy (SBRT) showed a 100% improvement in survival and favorable tumor eradication in a model of non-small cell lung cancer (NSCLC) compared to irradiation alone. These data were presented yesterday at the 105th Annual Meeting of the American Association for Cancer Research (AACR) being held in San Diego, California from April 5-9, 2014. Bavituximab is an investigational immunotherapy currently being evaluated in NSCLC as part of the SUNRISE pivotal Phase III clinical trial. Peregrine Pharmaceuticals (NASDAQ:PPHM), shares after opening at $1.99 moved to $2.09 on last trade day and at the end of the day closed at $1.89. Company price to sales ratio in past twelve months was calculated as 16.51 and price to cash ratio as 5.28. Peregrine Pharmaceuticals (NASDAQ:PPHM), showed a negative weekly performance of 0.53%.
One stock that might be an intriguing choice for investors right now is Intrexon Corporation (XON – Snapshot Report). This is because this security in the medical services space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. Intrexon Corp (NYSE:XON), shares fell 4.43% in last trading session and ended the day on $22.43. Intrexon Corp (NYSE:XON), return on equity ratio is recorded as 112.10% and its return on assets is -69.20%.
Immunomedics, Inc. (NASDAQ:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, announced that 5 patients reported a partial response as their best response, based on RECIST 1.1 criteria, in the Company’s ongoing Phase I/II clinical trial of its investigational antibody-drug conjugate (ADC), IMMU-132, in patients with solid cancers. IMMU-132 is an anti-TROP-2 antibody with SN-38, the active metabolite of irinotecan, linked to the antibody. Immunomedics, Inc. (NASDAQ:IMMU), shares moved up 1.80% in last trading session and was closed at $3.95, while trading in range of $3.75 – $4.22. Immunomedics, Inc. (NASDAQ:IMMU), year to date (YTD) performance is -14.13%.
Puma Biotechnology Inc (NYSE:PBYI), a development stage biopharmaceutical company, announced the presentation of positive results from the Phase II clinical trial of Puma’s investigational drug PB272 (neratinib) for the neoadjuvant treatment of breast cancer (I-SPY 2 TRIAL) in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2014 in San Diego, California. The presentation entitled “Neratinib plus Standard Neoadjuvant Therapy for High-Risk Breast Cancer: Efficacy Results from the I-SPY 2 TRIAL” was presented at the session entitled “Clinical Trials Symposium: Biomarker Driven Clinical Trials.” Puma Biotechnology Inc (NYSE:PBYI), weekly performance is -16.52%. On last trading day company shares ended up $86.94. Puma Biotechnology Inc (NYSE:PBYI),distance from 50-day simple moving average (SMA50) is -25.85%. Analysts mean target Price for the company is $134.50.